Lung Cancer Wherein Durvalumab Induced Both Anti-CRMP-5 Antibody-related Paraneoplastic Neurological Syndromes and Neurological Adverse Events
-
- Seki Tomokazu
- Department of Neurology, Faculty of Medicine, University of Toyama, Japan
-
- Baba Kousuke
- Department of Neurology, Faculty of Medicine, University of Toyama, Japan
-
- Hayashi Tomohiro
- Department of Neurology, Faculty of Medicine, University of Toyama, Japan
-
- Furuta Risako
- Department of Neurology, Faculty of Medicine, University of Toyama, Japan
-
- Hirosawa Hiroaki
- Department of Neurology, Faculty of Medicine, University of Toyama, Japan
-
- Mitsui Taichi
- Department of Neurology, Faculty of Medicine, University of Toyama, Japan
-
- Maesaka Hiroki
- Department of Neurology, Faculty of Medicine, University of Toyama, Japan
-
- Takasawa Syuhei
- Department of Neurology, Faculty of Medicine, University of Toyama, Japan
-
- Miwa Toshiro
- First Department of Internal Medicine, Toyama University Hospital, Japan
-
- Tanaka Keiko
- Department of Animal Model Development, Bioresource Science Branch, Center for Bioresource-based Research, Brain Research Institute, Niigata University, Japan
-
- Nakatsuji Yuji
- Department of Neurology, Faculty of Medicine, University of Toyama, Japan
Abstract
<p>A 68-year-old man with small-cell lung cancer developed anti-collapsin response-mediator protein (CRMP)-5 antibody-related paraneoplastic neurological syndrome (PNS) presenting with ataxia and chorea during treatment with durvalumab. As a result of steroid therapy, anti-CRMP-5 antibodies became negative, hyperintense lesions on brain magnetic resonance imaging disappeared, and neurological symptoms improved. After resuming durvalumab, he became unable to walk due to neurological adverse events (nAEs). There have been no reported cases manifesting PNSs and nAEs as a result of the same immune checkpoint inhibitors (ICIs) administered at different times. Resuming ICIs in patients diagnosed with PNSs should be performed with prudence. </p>
Journal
-
- Internal Medicine
-
Internal Medicine 63 (7), 1009-1014, 2024-04-01
The Japanese Society of Internal Medicine